Skip to main content

Advertisement

SpringerLink
Log in

Pretargeting: taking an alternate route for localizing radionuclides

  • Research Article
  • Published:
Tumor Biology

Abstract

Bispecific antibody pretargeting is a two-step procedure for selectively delivering radionuclides to tumors. The procedure was developed to solve a number of problems encountered when radionuclides are directly coupled to an IgG, such as slow blood clearance and delayed tumor accretion. While various forms of antibody fragments can reduce blood pool activity and provide faster tumor localization, tumor uptake is reduced considerably. In pretargeting procedures, the radionuclide is attached to a small molecule that quickly traverses the vascular barrier to reach the tumor cells, achieving maximum accretion within 0.5 to 1.0 h. Just as quickly, it is eliminated from the body, thereby minimizing tissue exposure and developing high tumor/tissue ratios very early. In order to capture the radionuclide in the tumor, a bispecific antibody (bsMAb) that binds to the tumor and to the isotope carrier (e.g., a hapten-peptide) is pre-administered some time earlier. The pretargeting procedure has been shown repeatedly to improve tumor localization as compared to directly radiolabeled antibodies, thereby enhancing both imaging and therapy. In this article, we review the progress our group has made toward developing and testing bsMAb pretargeting systems for cancer detection and therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Belda-Iniesta C, Ibanez de Caceres I, de Castro J. Monoclonal antibodies for medical oncology: a few critical perspectives. Clin Transl Oncol. 2011;13:84–7.

    Article  PubMed  CAS  Google Scholar 

  2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–74.

    Article  PubMed  CAS  Google Scholar 

  3. Reichert JM. Metrics for antibody therapeutics development. mAbs. 2010;2:695–700.

    Article  PubMed  Google Scholar 

  4. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226–43.

    Article  PubMed  Google Scholar 

  5. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349–70.

    Article  PubMed  Google Scholar 

  6. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720–34.

    Article  PubMed  CAS  Google Scholar 

  7. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM. Antibodies against metal chelates. Nature. 1985;316:265–8.

    Article  PubMed  CAS  Google Scholar 

  8. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990;50:2330–6.

    PubMed  CAS  Google Scholar 

  9. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med. 1998;42:225–41.

    PubMed  CAS  Google Scholar 

  10. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650–5.

    PubMed  CAS  Google Scholar 

  11. Stickney DR, Slater JB, Kirk GA, Anderson LD, Chang C-H, Frincke JM. Bifunctional antibody: ZCE/CHA 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjug Radiopharm. 1989;2:1–13.

    Google Scholar 

  12. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358–66.

    PubMed  Google Scholar 

  13. Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80:2618–23.

    Article  PubMed  CAS  Google Scholar 

  14. Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 1998;39:1937–43.

    PubMed  CAS  Google Scholar 

  15. Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med. 2000;41:480–7.

    PubMed  CAS  Google Scholar 

  16. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294–302.

    PubMed  CAS  Google Scholar 

  17. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155–9.

    PubMed  CAS  Google Scholar 

  18. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–34.

    Article  PubMed  CAS  Google Scholar 

  19. Axworthy DB, Fritzberg AR, Hylarides MD, Mallet RW, Theodore LJ, Gustavson LM, Su F-M, Beaumier PL, Reno JM. Preclinical evaulation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted 90Y radioimmunotherapy in a mouse xenograft model. J Immunother. 1994;16:158.

    Article  Google Scholar 

  20. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802–7.

    Article  PubMed  CAS  Google Scholar 

  21. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardies M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen × anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973S–81.

    PubMed  CAS  Google Scholar 

  22. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247–55.

    PubMed  CAS  Google Scholar 

  23. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–11.

    Article  PubMed  CAS  Google Scholar 

  24. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779–88.

    Article  PubMed  CAS  Google Scholar 

  25. DeNardo SJ, DeNardo GL, Brush J, Carter P. Phage library-derived human anti-TETA and anti-DOTA scFv for pretargeting RIT. Hybridoma. 1999;18:13–21.

    Article  PubMed  CAS  Google Scholar 

  26. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imag Biol. 2011;13:215–21.

    Article  Google Scholar 

  27. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol. 1990;27:995–1000.

    Article  PubMed  CAS  Google Scholar 

  28. Morel A, Darmon M, Delaage M. An immunoenzymoassay for histamine. Agents Actions. 1990;30:291–3.

    Article  PubMed  CAS  Google Scholar 

  29. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Milhaud G, Tartar A, Rostene W, Barbet J, Gruaz-Guyon A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem. 1997;8:526–33.

    Article  PubMed  CAS  Google Scholar 

  30. Hosono M, Hosono MN, Kraeber-Bodere F, Devys A, Thedrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med. 1999;40:1216–21.

    PubMed  CAS  Google Scholar 

  31. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354–63.

    PubMed  CAS  Google Scholar 

  32. McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678–88.

    PubMed  CAS  Google Scholar 

  33. Griffiths GL, Chang CH, McBride WJ, Rossi EA, Sheerin A, Tejada GR, Karacay H, Sharkey RM, Horak ID, Hansen HJ, Goldenberg DM. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med. 2004;45:30–9.

    PubMed  CAS  Google Scholar 

  34. Karacay H, Sharkey RM, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga. J Nucl Med. 2011;52:555–9.

    Article  PubMed  CAS  Google Scholar 

  35. McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–8.

    Article  PubMed  CAS  Google Scholar 

  36. McBride WJ, D’Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, Goldenberg DM. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331–40.

    Article  PubMed  CAS  Google Scholar 

  37. D’Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793–803.

    PubMed  Google Scholar 

  38. Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, Goldenberg DM. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005;11:7122s–9.

    Article  PubMed  CAS  Google Scholar 

  39. Rossi EA, Sharkey RM, McBride W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003;9:3886S–96.

    PubMed  CAS  Google Scholar 

  40. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841–6.

    Article  PubMed  CAS  Google Scholar 

  41. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158–63.

    Article  PubMed  CAS  Google Scholar 

  42. Rossi EA, Goldenberg DM, Chang CH: The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2011; doi: 10.1021/bc2004999PMID: 22168444.

  43. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody’s valency for the tumor target antigen. Bioconjug Chem. 2002;13:1054–70.

    Article  PubMed  CAS  Google Scholar 

  44. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250–5.

    Article  PubMed  CAS  Google Scholar 

  45. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11:7109s–21.

    Article  PubMed  CAS  Google Scholar 

  46. Sharkey RM, Karacay H, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin Cancer Res. 2007;13:5577s–85.

    Article  PubMed  CAS  Google Scholar 

  47. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin’s lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282–90.

    Article  PubMed  CAS  Google Scholar 

  48. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 2008;246:497–507.

    Article  PubMed  Google Scholar 

  49. Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50:444–53.

    Article  PubMed  CAS  Google Scholar 

  50. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190–203.

    Article  PubMed  Google Scholar 

  51. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11:7879–85.

    Article  PubMed  CAS  Google Scholar 

  52. Karacay H, Sharkey R, Rossi E, McBride B, Chang C-H, Goldenberg D: A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer. J Nucl Med 2010;51:Abst 1148.

  53. Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med. 2009;50:2008–16.

    Article  PubMed  Google Scholar 

  54. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, van der Graaf WT, Oyen WJ, Boerman OC. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019–27.

    Article  PubMed  CAS  Google Scholar 

  55. Frampas E, Maurel C, Remaud-Le Saec P, Mauxion T, Faivre-Chauvet A, Davodeau F, Goldenberg DM, Bardies M, Barbet J. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging. 2011;38:2153–64.

    Article  PubMed  CAS  Google Scholar 

  56. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros G. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113–47.

    PubMed  Google Scholar 

  57. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm. 2010;25:581–8.

    Article  PubMed  CAS  Google Scholar 

  58. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99.

    Article  PubMed  Google Scholar 

  59. Schoffelen R, Boerman OC, van der Graff WT, van Herpen CM, Sharkey RM, McBride WJ, Chang CH, Rossi EA, Goldenberg DM, Oyen WJ. Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): first results. J Nucl Med. 2011;52:107 (abstr 358).

    Article  Google Scholar 

  60. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, Rossi EA, Eek A, Oyen WJ, Boerman OC. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Habibe Karacay, Dr. Jacques Barbet, Prof Otto Boerman, Dr. Shankar Vallabhajosula, and Dr. Pat Zanzonico for their assistance in the preclinical studies.

Conflict of interest

C-H Chang, EA Rossi, WJ McBride, and DM Goldenberg are employed or have financial interests in IBC Pharmaceuticals, Inc., and/or Immunomedics, Inc. RM Sharkey has no disclosure.

Author information

Authors and Affiliations

  1. Garden State Cancer Center at the Center for Molecular Medicine and Immunology, 300 The American Road, Morris Plains, 07950, NJ, USA

    Robert M. Sharkey & David M. Goldenberg

  2. Immunomedics, Inc., 300 The American Road, Morris Plains, 07950, NJ, USA

    Chien-Hsing Chang & William J. McBride

  3. IBC Pharmaceuticals, Inc. and Immunomedics, Inc., 300 The American Road, Morris Plains, 07950, NJ, USA

    Edmund A. Rossi

Authors
  1. Robert M. Sharkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chien-Hsing Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edmund A. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William J. McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David M. Goldenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert M. Sharkey.

Additional information

Pretargeting radionuclides with bispecific antibodies enhances tumor localization for improved imaging and therapy of cancer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharkey, R.M., Chang, CH., Rossi, E.A. et al. Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol. 33, 591–600 (2012). https://doi.org/10.1007/s13277-012-0367-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0367-6

Keywords

Search

Navigation